Template:Epiglottitis Antibiotics - Revision history

Danbot: Add pediatric immunocompetent and immunocompromised dosing

2026-03-20T12:52:17Z

Add pediatric immunocompetent and immunocompromised dosing

← Older revision		Revision as of 12:52, 20 March 2026
Line 11:		Line 11:
	Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans		Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
	*{{AntibioticDose\|disease=Epiglottitis\|drug=Cefepime\|dose=2g (50/kg) IV q8 hours\|context=Immunocompromised}} AND {{AntibioticDose\|disease=Epiglottitis\|drug=Vancomycin\|dose=15mg/kg IV q6 hours\|context=Immunocompromised}}		*{{AntibioticDose\|disease=Epiglottitis\|drug=Cefepime\|dose=2g (50/kg) IV q8 hours\|context=Immunocompromised}} AND {{AntibioticDose\|disease=Epiglottitis\|drug=Vancomycin\|dose=15mg/kg IV q6 hours\|context=Immunocompromised}}

			====Pediatric Immunocompetent====
			*{{AntibioticDose\|disease=Epiglottitis\|drug=Ceftriaxone\|dose=50-100mg/kg IV daily (max 2g)\|context=Pediatric Immunocompetent\|population=Pediatric}} (first line) OR
			*{{AntibioticDose\|disease=Epiglottitis\|drug=Cefotaxime\|dose=50mg/kg IV q8hrs (max 2g/dose)\|context=Pediatric Immunocompetent\|population=Pediatric}} OR
			*{{AntibioticDose\|disease=Epiglottitis\|drug=Ampicillin/Sulbactam\|dose=50mg/kg IV q6hrs (max 3g/dose)\|context=Pediatric Immunocompetent\|population=Pediatric}}
			*Consider {{AntibioticDose\|disease=Epiglottitis\|drug=Vancomycin\|dose=15mg/kg IV q6hrs\|context=Pediatric, MRSA risk\|population=Pediatric}} if risk of [[MRSA]]

			====Pediatric Immunocompromised====
			*{{AntibioticDose\|disease=Epiglottitis\|drug=Cefepime\|dose=50mg/kg IV q8hrs (max 2g)\|context=Pediatric Immunocompromised\|population=Pediatric}} AND {{AntibioticDose\|disease=Epiglottitis\|drug=Vancomycin\|dose=15mg/kg IV q6hrs\|context=Pediatric Immunocompromised\|population=Pediatric}}

Danbot: Add disease=Epiglottitis parameter to AntibioticDose calls - fixes aggregation page display issue

2026-03-19T23:12:14Z

Add disease=Epiglottitis parameter to AntibioticDose calls - fixes aggregation page display issue

← Older revision		Revision as of 23:12, 19 March 2026
Line 2:		Line 2:

	====Immunocompetent====		====Immunocompetent====
	*{{AntibioticDose\|drug=Ceftriaxone\|dose=2gm IV once daily\|context=Immunocompetent}} (first line) OR		*{{AntibioticDose\|disease=Epiglottitis\|drug=Ceftriaxone\|dose=2gm IV once daily\|context=Immunocompetent}} (first line) OR
	*{{AntibioticDose\|drug=Cefotaxime\|dose=2gm (50mg/kg) IV three times daily\|context=Immunocompetent}} OR		*{{AntibioticDose\|disease=Epiglottitis\|drug=Cefotaxime\|dose=2gm (50mg/kg) IV three times daily\|context=Immunocompetent}} OR
	*{{AntibioticDose\|drug=Ampicillin/Sulbactam\|dose=3g (50mg/kg) IV q 6 hours\|context=Immunocompetent}} OR		*{{AntibioticDose\|disease=Epiglottitis\|drug=Ampicillin/Sulbactam\|dose=3g (50mg/kg) IV q 6 hours\|context=Immunocompetent}} OR
	*{{AntibioticDose\|drug=Levofloxacin\|dose=750mg IV once daily\|context=Immunocompetent}}		*{{AntibioticDose\|disease=Epiglottitis\|drug=Levofloxacin\|dose=750mg IV once daily\|context=Immunocompetent}}
	*Consider {{AntibioticDose\|drug=Vancomycin\|dose=15-20mg/kg IV\|context=Immunocompetent, MRSA risk}} to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>		*Consider {{AntibioticDose\|disease=Epiglottitis\|drug=Vancomycin\|dose=15-20mg/kg IV\|context=Immunocompetent, MRSA risk}} to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>

	====Immunocompromised====		====Immunocompromised====
	Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans		Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
	*{{AntibioticDose\|drug=Cefepime\|dose=2g (50/kg) IV q8 hours\|context=Immunocompromised}} AND {{AntibioticDose\|drug=Vancomycin\|dose=15mg/kg IV q6 hours\|context=Immunocompromised}}		*{{AntibioticDose\|disease=Epiglottitis\|drug=Cefepime\|dose=2g (50/kg) IV q8 hours\|context=Immunocompromised}} AND {{AntibioticDose\|disease=Epiglottitis\|drug=Vancomycin\|dose=15mg/kg IV q6 hours\|context=Immunocompromised}}

Danbot: Convert to {{AntibioticDose}} for SMW antibiotic-disease linking

2026-03-19T20:50:03Z

Convert to {{AntibioticDose}} for SMW antibiotic-disease linking

← Older revision		Revision as of 20:50, 19 March 2026
Line 1:		Line 1:
	Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae		Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae

	====Immunocompetent====		====Immunocompetent====
	*[[Ceftriaxone]] 2gm IV once daily (first line) OR		*{{AntibioticDose\|drug=Ceftriaxone\|dose=2gm IV once daily\|context=Immunocompetent}} (first line) OR
	*[[Cefotaxime]] 2gm (50mg/kg) IV three times daily OR		*{{AntibioticDose\|drug=Cefotaxime\|dose=2gm (50mg/kg) IV three times daily\|context=Immunocompetent}} OR
	*[[Ampicillin/Sulbactam]] 3g (50mg/kg) IV q 6 hours OR		*{{AntibioticDose\|drug=Ampicillin/Sulbactam\|dose=3g (50mg/kg) IV q 6 hours\|context=Immunocompetent}} OR
	*[[Levofloxacin]] 750mg IV once daily		*{{AntibioticDose\|drug=Levofloxacin\|dose=750mg IV once daily\|context=Immunocompetent}}
	*Consider [[Vancomycin]] 15-20mg/kg IV to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>		*Consider {{AntibioticDose\|drug=Vancomycin\|dose=15-20mg/kg IV\|context=Immunocompetent, MRSA risk}} to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>

	====Immunocompromised====		====Immunocompromised====
	Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans		Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
	*[[Cefepime]] 2g (50/kg) IV q8 hours AND [[Vancomycin]] 15mg/kg IV q6 hours		*{{AntibioticDose\|drug=Cefepime\|dose=2g (50/kg) IV q8 hours\|context=Immunocompromised}} AND {{AntibioticDose\|drug=Vancomycin\|dose=15mg/kg IV q6 hours\|context=Immunocompromised}}

Gheid: /* Immunocompetent */

2019-06-23T17:21:25Z

Immunocompetent

← Older revision		Revision as of 17:21, 23 June 2019
Line 5:		Line 5:
	*[[Ampicillin/Sulbactam]] 3g (50mg/kg) IV q 6 hours OR		*[[Ampicillin/Sulbactam]] 3g (50mg/kg) IV q 6 hours OR
	*[[Levofloxacin]] 750mg IV once daily		*[[Levofloxacin]] 750mg IV once daily
	*Consider [[Vancomycin]] 15-20mg/kg to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>		*Consider [[Vancomycin]] 15-20mg/kg IV to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>

	====Immunocompromised====		====Immunocompromised====
	Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans		Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
	*[[Cefepime]] 2g (50/kg) IV q8 hours AND [[Vancomycin]] 15mg/kg IV q6 hours		*[[Cefepime]] 2g (50/kg) IV q8 hours AND [[Vancomycin]] 15mg/kg IV q6 hours

Yoshmd: Created page with "Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae ====Immunocompetent==== *Ceftriaxone 2gm IV once dail..."

2015-04-07T00:55:38Z

Created page with "Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae ====Immunocompetent==== *Ceftriaxone 2gm IV once dail..."

New page

Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae
====Immunocompetent====
*[[Ceftriaxone]] 2gm IV once daily (first line) OR
*[[Cefotaxime]] 2gm (50mg/kg) IV three times daily OR
*[[Ampicillin/Sulbactam]] 3g (50mg/kg) IV q 6 hours OR
*[[Levofloxacin]] 750mg IV once daily
*Consider [[Vancomycin]] 15-20mg/kg to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>
====Immunocompromised====
Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
*[[Cefepime]] 2g (50/kg) IV q8 hours AND [[Vancomycin]] 15mg/kg IV q6 hours

← Older revision		Revision as of 23:12, 19 March 2026
Line 2:		Line 2:

	====Immunocompetent====		====Immunocompetent====
	*{{AntibioticDose\|drug=Ceftriaxone\|dose=2gm IV once daily\|context=Immunocompetent}} (first line) OR		*{{AntibioticDose\|disease=Epiglottitis\|drug=Ceftriaxone\|dose=2gm IV once daily\|context=Immunocompetent}} (first line) OR
	*{{AntibioticDose\|drug=Cefotaxime\|dose=2gm (50mg/kg) IV three times daily\|context=Immunocompetent}} OR		*{{AntibioticDose\|disease=Epiglottitis\|drug=Cefotaxime\|dose=2gm (50mg/kg) IV three times daily\|context=Immunocompetent}} OR
	*{{AntibioticDose\|drug=Ampicillin/Sulbactam\|dose=3g (50mg/kg) IV q 6 hours\|context=Immunocompetent}} OR		*{{AntibioticDose\|disease=Epiglottitis\|drug=Ampicillin/Sulbactam\|dose=3g (50mg/kg) IV q 6 hours\|context=Immunocompetent}} OR
	*{{AntibioticDose\|drug=Levofloxacin\|dose=750mg IV once daily\|context=Immunocompetent}}		*{{AntibioticDose\|disease=Epiglottitis\|drug=Levofloxacin\|dose=750mg IV once daily\|context=Immunocompetent}}
	*Consider {{AntibioticDose\|drug=Vancomycin\|dose=15-20mg/kg IV\|context=Immunocompetent, MRSA risk}} to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>		*Consider {{AntibioticDose\|disease=Epiglottitis\|drug=Vancomycin\|dose=15-20mg/kg IV\|context=Immunocompetent, MRSA risk}} to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>

	====Immunocompromised====		====Immunocompromised====
	Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans		Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
	*{{AntibioticDose\|drug=Cefepime\|dose=2g (50/kg) IV q8 hours\|context=Immunocompromised}} AND {{AntibioticDose\|drug=Vancomycin\|dose=15mg/kg IV q6 hours\|context=Immunocompromised}}		*{{AntibioticDose\|disease=Epiglottitis\|drug=Cefepime\|dose=2g (50/kg) IV q8 hours\|context=Immunocompromised}} AND {{AntibioticDose\|disease=Epiglottitis\|drug=Vancomycin\|dose=15mg/kg IV q6 hours\|context=Immunocompromised}}